News from genzyme A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 25, 2015, 09:00 ET Prince Edward Island funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, May 25, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that PEI Pharmacare has included AUBAGIO™...


Apr 27, 2015, 13:11 ET Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years

- Approximately 70 per cent of Lemtrada Patients Had Not Received Any Additional Lemtrada Treatment in the Prior Three Years - MISSISSAUGA, ON, April 27, 2015 /CNW/ - Genzyme, a Sanofi company,...


Mar 20, 2015, 13:01 ET Newfoundland and Labrador funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, March 20, 2015 /CNW/- Genzyme, a Sanofi company, announced today that the Newfoundland and Labrador Prescription Drug...


Jan 16, 2015, 09:43 ET Manitoba funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Jan. 16, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that the Manitoba Drug Program has included AUBAGIO™...


Jan 05, 2015, 11:40 ET Nova Scotia funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Jan. 5, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that the Nova Scotia Drug Program has included AUBAGIO™ ...


Dec 18, 2014, 12:08 ET The Yukon to fund treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Dec. 18, 2014 /CNW/ - Genzyme, a sanofi company, announced today that the Yukon Pharmaceutical Programs have included...


Dec 11, 2014, 11:00 ET British Columbia funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Dec. 11, 2014 /CNW/ - Genzyme, a Sanofi company, announced today that the British Columbia drug program, PharmaCare,...


Dec 01, 2014, 13:05 ET Alberta funds treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Dec. 1, 2014 /CNW/ - Genzyme, a sanofi company, announced today that the Alberta Drug Program has included AUBAGIO®...


Nov 20, 2014, 08:00 ET Ontario funds AUBAGIO® for relapsing remitting multiple sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Nov. 20, 2014 /CNW/ - Genzyme, a sanofi company, announced today that the Ontario Public Drug Benefit Program has...


Nov 04, 2014, 11:04 ET Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis

Select Canadian clinics to participate in study MISSISSAUGA, ON, Nov. 4, 2014 /CNW/ - Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical...


May 01, 2014, 10:24 ET Slowing of Brain Atrophy and Reductions in New MS Lesions Sustained at Three Years in Patients Treated with Genzyme's Lemtrada(TM)

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not ...


Feb 28, 2014, 07:00 ET /R E P E A T -- Video B-Roll available via CNW - First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada/

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of...


Feb 27, 2014, 15:00 ET /R E P E A T -- Video B-Roll available via CNW - First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada/

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of...


Feb 27, 2014, 08:00 ET First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada

MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™ (alemtuzumab) for the management of adult patients with relapsing-remitting...


Feb 27, 2014, 08:00 ET Video B-Roll available via CNW - First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of...


Nov 20, 2013, 08:00 ET Health Canada Approves Genzyme's AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis

MISSISSAUGA, ON, Nov. 20, 2013 /CNW/ - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIO® (teriflunomide) 14 mg as monotherapy for the treatment of patients with...


Feb 27, 2013, 12:41 ET Genzyme Recognizes International Rare Disease Day with the launch of a new website and the Third Annual Patient Advocacy Leadership Awards

TORONTO, Feb. 27, 2013 /CNW/ - Genzyme, a Sanofi company, today announced its support of International Rare Disease Day with a series of initiatives meant to call attention to rare diseases as an...


Oct 12, 2012, 15:07 ET Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability

- AUBAGIO 14 mg is the Only Oral MS Therapy to Significantly Delay Progression of Disability Across Two Phase III Studies - TORONTO, Oct. 12, 2012 /CNW/ - Sanofi (EURONEXT: SAN and NYSE: SNY) and its ...


Oct 03, 2012, 13:00 ET Genzyme Applauds Health Canada for Focusing on Patients with Rare Diseases

MISSISSAUGA, ON, Oct. 3, 2012 /CNW/ - Genzyme, a Sanofi company fully supports the move by Health Canada to accelerate approval and access to orphan drugs, as well as information through...


Feb 29, 2012, 09:00 ET Genzyme Recognizes International Rare Disease Day with Second Annual Patient Advocacy Grant Program

TORONTO, Feb. 29, 2012 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of events to celebrate and...